New Horizons in Melanoma Treatment--Bridging The Treatment Gap: Highlights from MRA's 9th Annual Scientific Retreat
This year, the Ninth Annual Scientific Retreat was held February 13-15, 2017, in Washington, DC, with nearly 300 registrants. Attendees included academic investigators, pharmaceutical and biotech representatives, melanoma advocates from numerous non-profit organizations, donors and government officials.
Featured in this report are some of our key achievements from the past year. These accomplishments highlight our capacity to partner with stakeholders and fund scientific studies that will accelerate transformative advances in melanoma research.
MRA's Eighth Scientific Retreat was held on February 24-26 in Washington, DC. Our Eighth Annual Scientific Retreat Report highlights the new frontier in melanoma research. Participants included leading scientists from the United States and abroad, as well as senior leadership from non-profit foundations, government agencies, industry, and other like-minded organizations. Leading experts from across the melanoma research continuum engaged in discussions of cutting-edge research results from MRA-funded programs as well as on topics of special interest.
This report marks another groundbreaking year of progress for patients with melanoma. The approvals of new therapies, whether alone or
in combination with others, underscore the tremendous advancements in treatment option.
The 2013-2014 Progress Report highlights the year's incredible achievements and advancements made on behalf of melanoma patients and our continued strategy to build upon innovative developments in the field.
The Melanoma Research Alliance (MRA) works closely with public policy leaders, catalyzing efforts to propel strategic policy initiatives that can advance the fight against melanoma. This document provides an overview of current policy initiatives.
MRA convened its Fifth Annual Scientific Retreat in Washington, DC, February 27-28, 2013. The retreat brought together nearly 200 leading scientists and clinicians from around the world, as well as senior leadership from nonprofit foundations, corporate allies, government agencies, industry, and other key stakeholders to share early findings, identify future directions, discuss ideas, and look for synergies and partnerships.
The MRA brochure features ways in which MRA is working toward a cure through research, fostering collaboration to amplify our reach, and leveraging progress through policy change.
Stand Up To Cancer (SU2C) and the Melanoma Research Alliance (MRA) have joined forces with a new print public service announcement starring Academy Award® nominee Laura Linney. Headlined “Wear Your Beauty Brilliantly,” the PSA is designed to raise awareness about the life-saving benefits of protecting oneself from harmful exposure to UV rays that increase the risk of being diagnosed with melanoma and is the first element in a “Protect Your Skin” campaign.
Building on the Momentum, Charting the Course: Highlights from the Fourth Annual MRA Scientific Retreat
MRA's Fourth Annual Scientific Retreat brought together more than 220 thought leaders from academia, industry, government, business, and philanthropy to share latest findings and forge new partnerships in pursuit of better outcomes for patients. This report summarizes the meeting highlights, underscoring the momentum that has occurred due to recent research breakthroughs and opportunities for charting a new course in the fight against melanoma.
The 2012-2013 Snapshot of Progress reflects on the organization's accomplishments and the impact of MRA-funded programs during this pivotal time in melanoma research.
At MRA's Third Annual Scientific Retreat, held Feb. 16-18, 2011, in Washington, DC, MRA hosted discussions of cutting-edge melanoma research results and key policy issues. MRA-funded investigators, including early career scientists, established investigators, and interdisciplinary teams, reported on the progress of their work. The report summarizes the highlights of the meeting, illustrating the progress that has been made as a result of collaborative partnerships to forge pathways towards success in the fight against melanoma.